

Supplementary Table 1. Eradication rates in the per-protocol analysis of sequential therapy and triple therapy according to clarithromycin and metronidazole resistance-Combined analysis including the two studies

Resistance	Study	S14	S10	T14
CLA-S and MET-S	Liou et al. 2013	99.1% (116/117)	95.3% (123/129)	89.9% (98/109)
	Present study		95.5% (257/269)	96.4% (244/253)
	Combined		95.4% (380/398)	94.4% (342/362)
CLA-S and MET-R	Liou et al. 2013	90.9% (30/33)	78.4% (29/37)	92.9% (39/42)
	Present study		93.5% (72/77)	95.6% (86/90)
	Combined		91.8%(101/110)	94.7% (125/132)
CLA-R and MET-S	Liou et al. 2013	71.4% (10/14)	70% (7/10)	56.3% (9/16)
	Present study		75% (18/24)	57.1% (8/14)
	Combined		73.5% (25/34)	56.7% (17/30)
CLA-R and MET-R	Liou et al. 2013	0% (0/1)	42.9% (3/7)	50% (2/4)
	Present study		52.9% (9/17)	38.9% (7/18)
	Combined		50% (12/24)	40.1% (9/22)

S14: sequential therapy for 14 days; S10: sequential therapy for 10 days; T14: triple therapy for 14 days;

CLA-S: clarithromycin susceptible; MET-S: metronidazole susceptible; CLA-R: clarithromycin resistant;

MET-R: metronidazole resistant.